Two stocks in Healthcare
Fresenius SE & Co. KGaA vs Merck KGaA: profit, growth, debt and price compared
Fresenius SE & Co. KGaA is stronger on 5 of 7 figures: sales growth, price for its expected profit, dividend, analysts' view and price trend. Merck KGaA is stronger on 2: profit margin and debt.
Save both stocks to your watchlist and revisit their latest fundamentals.
| Fresenius SE & Co. KGaAFRE.DE | Merck KGaAMRK.DE | |
|---|---|---|
| Net margin | 6.6% | Stronger: 8.9% |
| Revenue growth, past year | Stronger: +5.90% | +5.80% |
| Debt to equity | 57.0% | Stronger: 38.1% |
| Forward P/E | Stronger: 13.7× | 16.4× |
| Dividend yield | Stronger: 1.95% | 1.47% |
| Analysts | Stronger: Strong buy · 14 | Buy · 14 |
| From its 200-day average | Stronger: +19.2% | +11.7% |
Share price over the past year
- Fresenius SE & Co. KGaA+14.2%
- Merck KGaA+35.2%
20 Nov 202518 Nov 2026
Fresenius SE & Co. KGaA or Merck KGaA: which is stronger?
- MRK.DE
Which is more profitable?
Merck KGaA keeps more of each sale as profit: 8.9% against 6.6%.
- FRE.DE
Which is growing its sales faster?
Fresenius SE & Co. KGaA is growing its sales faster: +5.90% over the past year, against +5.80%.
- MRK.DE
Which has borrowed less?
Merck KGaA has borrowed less: its debt is 38.1% of what its shareholders own, against 57.0% for Fresenius SE & Co. KGaA.
- FRE.DE
Which costs less for the profit it is expected to make?
Fresenius SE & Co. KGaA costs less for the profit it is expected to make: 13.7× its forward earnings, against 16.4×.
- FRE.DE
Which pays more in dividends?
Fresenius SE & Co. KGaA pays more back in dividends for what a share costs: 1.95% a year, against 1.47%.
- FRE.DE
Which do analysts rate higher?
Analysts are warmer on Fresenius SE & Co. KGaA: Strong buy, against Buy for Merck KGaA.
- FRE.DE
Which is in the stronger price trend?
Fresenius SE & Co. KGaA's price is in the stronger trend: 19.2% above its 200-day average, against 11.7% above.
What each company does
FRE.DEFresenius SE & Co. KGaA
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients in North America, Europe, the Asia-Pacific, Latin America, and Africa.
Reports results on 24 February 2027
MRK.DEMerck KGaA
Merck KGaA operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific.
Reports results on 4 March 2027
This comparison is just the starting point.
Discover opportunities, understand companies and compare investments in one place. See how StratDeck works
Keep researching
Where next
More comparisons
Free email
Up to speed in minutes, four times a week
Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.
Early access
Become a StratDeck founding user
Use StratDeck, tell us what's missing, and help decide what we build next.
100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.